Glenmark Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was ₹143,586 Mil.
During the past 12 months, Glenmark Pharmaceuticals's average Total Assets Growth Rate was -30.10% per year.
During the past 3 years, the average Total Assets Growth Rate was -4.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 3.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 6.80% per year.
During the past 13 years, Glenmark Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 60.10%. The lowest was -4.50%. And the median was 11.55%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Glenmark Pharmaceuticals's Total Assets for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals (NSE:GLENMARK) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Glenmark Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Glenmark Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:GLENMARK has been successfully added to your 